Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1673394 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Follistatin-Like 3 (Secreted Glycoprotein) (FSTL3) (Middle Region) antibody
- Antibody type
- Polyclonal
- Antigen
- A synthetic peptide corresponding to a sequence in the middle region of human FSTL3, different from the related rat and mouse sequences by one amino acid.Immunogen affinity purified.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- Middle Region
- Isotype
- IgG
- Vial size
- 100 μg
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.
- Handling
- Avoid repeated freezing and thawing.
Submitted references FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.
Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family.
FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders.
Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, Bloch KD, Thomas MK, Schneyer AL
Proceedings of the National Academy of Sciences of the United States of America 2007 Jan 23;104(4):1348-53
Proceedings of the National Academy of Sciences of the United States of America 2007 Jan 23;104(4):1348-53
Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family.
Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H
The Journal of biological chemistry 2000 Dec 29;275(52):40788-96
The Journal of biological chemistry 2000 Dec 29;275(52):40788-96
FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders.
Hayette S, Gadoux M, Martel S, Bertrand S, Tigaud I, Magaud JP, Rimokh R
Oncogene 1998 Jun 4;16(22):2949-54
Oncogene 1998 Jun 4;16(22):2949-54
No comments: Submit comment
No validations: Submit validation data